Compare LNTH & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | CRDO |
|---|---|---|
| Founded | 1956 | 2008 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 50.7B |
| IPO Year | 2014 | 2022 |
| Metric | LNTH | CRDO |
|---|---|---|
| Price | $100.64 | $186.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $87.00 | ★ $179.62 |
| AVG Volume (30 Days) | 903.8K | ★ 7.2M |
| Earning Date | 05-07-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 765.52 |
| EPS | ★ 2.91 | 0.67 |
| Revenue | $343,374,000.00 | ★ $1,335,116,000.00 |
| Revenue This Year | N/A | $210.92 |
| Revenue Next Year | $14.19 | $57.22 |
| P/E Ratio | ★ $34.57 | $261.92 |
| Revenue Growth | 3.62 | ★ 205.68 |
| 52 Week Low | $49.67 | $86.49 |
| 52 Week High | $111.86 | $308.67 |
| Indicator | LNTH | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 46.81 |
| Support Level | $100.51 | $170.90 |
| Resistance Level | $101.43 | $204.97 |
| Average True Range (ATR) | 0.45 | 9.59 |
| MACD | 0.09 | 1.37 |
| Stochastic Oscillator | 41.96 | 48.31 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.